BC Cancer, part of the Provincial Health Services Authority

Published purpose

This project build on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The overarching goal of the Project is to build much needed capacity in point-of-care (POC) manufacturing to support the clinical rollout of novel CAR T-cell products and other personalized cell therapy products with the addition of new POC manufacturing and clinical sites. The Conconi Family Immunotherapy Lab (CFIL) at BC Cancer is the first of four sites to be established and expanded. In parallel, and with direct involvement of the NRC, it will be aimed to initiate a minimum of two new, high-content, academically motivated clinical trials to be completed within the next five years for the benefit of cancer patients from across Canada.